Horizon Pharma plc Form SC 13G/A February 14, 2018

### SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

### **SCHEDULE 13G**

(Rule 13d-102)

### INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

### TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

### PURSUANT TO RULE 13d-2(b)

(Amendment No. 5) \*

Horizon Pharma PLC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

G4617B105

(CUSIP Number)

December 31, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

(Page 1 of 15 Pages)

\_\_\_\_\_

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

#### CUSIP No. G4617B10513GPage 2 of 15

NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) 1. Deerfield Mgmt, L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a) 2. (b) SEC USE ONLY 3. CITIZENSHIP OR PLACE OF ORGANIZATION 4. Delaware SOLE VOTING POWER 5. NUMBER OF 0 SHARED VOTING POWER SHARES 6. BENEFICIALLY 6,341,894 (1) OWNED BY SOLE DISPOSITIVE POWER 7. EACH REPORTING 0 PERSON 8. SHARED DISPOSITIVE POWER WITH

	<b>551</b>
9.	6,341,894 (1) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10.	6,341,894 (1) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
	3.87% TYPE OF REPORTING PERSON*
12.	
	PN

<sup>(1)</sup> Comprised of shares of common stock held by Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P., Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P., of which Deerfield Mgmt, L.P. is the general partner.

# CUSIP No. G4617B10513GPage 3 of 15

	NAME OF REPORTING PERSONS	
1.	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY	)
2.	Deerfield Management Company, L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) (b)
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware SOLE VOTING POWER 5.	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH	0 SHARED VOTING POWER 6. 6,341,894 (2) SOLE DISPOSITIVE POWER 7.	
REPORTING PERSON WITH	0 SHARED DISPOSITIVE POWER 8.	
	6,341,894 (2)	

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10.	6,341,894 (2) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
	3.87% TYPE OF REPORTING PERSON*
12.	PN

<sup>(2)</sup> Comprised of shares of common stock held by Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P., Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P., of which Deerfield Management Company, L.P. is the investment advisor.

# CUSIP No. G4617B10513GPage 4 of 15

	NAME OF REPORTING PERSONS	
1.	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY	<u>(</u> )
2.	Deerfield Partners, L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) (b)
2	SEC USE ONLY	
3. 4.	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware SOLE VOTING POWER 5.	
NUMBER OF SHARES BENEFICIALLY OWNED BY	0 SHARED VOTING POWER 6. 2,317,371 SOLE DISPOSITIVE POWER 7.	
EACH REPORTING PERSON	0 SHARED DISPOSITIVE POWER 8.	
WITH	2,317,371	

# AGGREGATE AMOUNTBENEFICIALLY OWNED BY EACH9. REPORTING PERSON

2,317,371

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

10.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

11.

1.41% TYPE OF REPORTING PERSON\*

12.

PN

# CUSIP No. G4617B10513GPage 5 of 15

	NAME OF REPORTING PERSONS	
1.	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY	<b>(</b> )
2.	Deerfield Special Situations Fund, L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) (b)
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware SOLE VOTING POWER 5.	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH	0 SHARED VOTING POWER 6. 624,965 SOLE DISPOSITIVE POWER 7.	
REPORTING PERSON WITH	0 SHARED DISPOSITIVE POWER 8.	
	624,965	

# AGGREGATE AMOUNTBENEFICIALLY OWNED BY EACHREPORTING PERSON

624,965

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

10.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

11.

0.38% TYPE OF REPORTING PERSON\*

12.

PN

# CUSIP No. G4617B10513GPage 6 of 15

	NAME OF REPORTING PERSONS	
1.	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)	)
2.		P. (a) (b)
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION	
	British Virgin Islands SOLE VOTING POWER 5.	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH	<ul> <li>0</li> <li>SHARED VOTING POWER</li> <li>6.</li> <li>1,264,347</li> <li>SOLE DISPOSITIVE POWER</li> <li>7.</li> </ul>	
REPORTING PERSON WITH	0 SHARED DISPOSITIVE POWER 8.	
	1,264,347	

# AGGREGATE AMOUNTBENEFICIALLY OWNED BY EACH9. REPORTING PERSON

1,264,347

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

10.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

11.

0.77% TYPE OF REPORTING PERSON\*

12.

PN

# CUSIP No. G4617B10513GPage 7 of 15

	NAME OF REPORTING PERSONS	
1.	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY	Y)
2.	Deerfield Private Design Fund II, L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) (b)
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware SOLE VOTING POWER 5.	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH	0 SHARED VOTING POWER 6. 995,008 SOLE DISPOSITIVE POWER 7.	
REPORTING PERSON WITH	0 SHARED DISPOSITIVE POWER 8.	
	995,008	

# AGGREGATE AMOUNTBENEFICIALLY OWNED BY EACHREPORTING PERSON

995,008

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

10.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

11.

0.61% TYPE OF REPORTING PERSON\*

12.

PN

# CUSIP No. G4617B10513GPage 8 of 15

	NAME OF REPORTING PERSONS	
1.	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY	)
	Deerfield Private Design International II L.P.	[,
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a)
2.		(b)
	SEC USE ONLY	
3.		
	CITIZENSHIP OR PLACE OF ORGANIZATION	
4.		
	British Virgin Islands SOLE VOTING POWER	
	5.	
NUMBER OF	0	
SHARES	SHARED VOTING POWER	
BENEFICIALLY	6.	
OWNED BY	1,140,203 SOLE DISPOSITIVE POWER	
EACH	7.	
REPORTING	0	
PERSON	8. SHARED DISPOSITIVE POWER	
WITH		

1,140,203

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,140,203

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

10.

9.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

11.

0.70%

## **TYPE OF REPORTING PERSON\***

12.

PN

#### CUSIP No. G4617B10513GPage 9 of 15

# NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) 1. James E. Flynn CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a) 2. (b) SEC USE ONLY 3. CITIZENSHIP OR PLACE OF ORGANIZATION 4. United States SOLE VOTING POWER 5. 0 NUMBER OF SHARED VOTING POWER **SHARES** 6. BENEFICIALLY 6,341,894 (3) OWNED BY SOLE DISPOSITIVE POWER 7. EACH REPORTING 0 SHARED DISPOSITIVE POWER PERSON 8. WITH 6,341,894 (3)

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10.	6,341,894 (3) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
	3.87% TYPE OF REPORTING PERSON*
12.	
	IN

<sup>(3)</sup> Comprised of shares of common stock held by Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P., Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P.

### Edgar Filing: Horizon Pharma plc - Form SC 13G/A

#### CUSIP No. G4617B10513GPage 10 of 15

Item 1(a). Name of Issuer:

Horizon Pharma PLC

Item 1(b). Address of Issuer's Principal Executive Offices:

Connaught House, 1<sup>st</sup> Floor 1 Burlington Road Dublin 4, D04 C5Y6, Ireland

Item 2(a). Name of Person Filing:

James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P., Deerfield Special Situations Fund, L.P., Deerfield Management Company, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P.

Item 2(b). Address of Principal Business Office, or if None, Residence:

James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P., Deerfield Special Situations Fund, L.P., Deerfield Management Company, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017

Item 2(c). Citizenship:

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Private Design Fund II, L.P. - Delaware limited partnerships;

Deerfield International Master Fund, L.P. and Deerfield Private Design International II, L.P., - British Virgin Islands limited partnerships;

James E. Flynn – United States citizen

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP Number:

G4617B105

- Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
- (a) Broker or dealer registered under Section 15 of the Exchange Act.
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) Investment company registered under Section 8 of the Investment Company Act.
- (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

## Edgar Filing: Horizon Pharma plc - Form SC 13G/A

CUSIP No. G4617B10513GPage 11 of 15

- (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned\*\*:

Deerfield Mgmt, L.P. – 6,341,894 shares

Deerfield Management Company, L.P. - 6,341,894 shares

Deerfield Partners, L.P. - 2,317,371 shares

Deerfield Special Situations Fund, L.P. – 624,965 shares

Deerfield International Master Fund, L.P. – 1,264,347 shares

Deerfield Private Design Fund II, L.P. - 995,008 shares

Deerfield Private Design International II, L.P. – 1,140,203 shares

James E. Flynn - 6,341,894 shares

(b) Percent of class\*\*:

Deerfield Mgmt, L.P. - 3.87%

	Edgar Filing: Horizor	n Pharma plc - Form SC 13G/A	
	Deerfield Management Company, L.P 3.879	%	
	Deerfield Partners, L.P. – 1.41%		
	Deerfield Special Situations Fund, L.P. – 0.38	%	
Deerfield International Master Fund, L.P. – 0.77%			
	Deerfield Private Design Fund II, L.P. – 0.61%		
	Deerfield Private Design International II, L.P.	- 0.70%	
	James E. Flynn – 3.87%		
	Number of shares as to which such person has**:		
	(i) Sole power to vote or to direct the vote:	All Reporting Persons - 0	
		Deerfield Mgmt, L.P 6,341,894	
	(ii) Shared power to vote or to direct the vote:	Deerfield Management Company, L.P 6,341,894	
		Deerfield Partners, L.P 2,317,371	
		Deerfield Special Situations Fund, L.P 624,965	
		Deerfield International Master Fund, L.P 1,264,347	
		Deerfield Private Design Fund II, L.P. – 995,008	
		Deerfield Private Design International II, L.P. – 1,140,203	

(c)

CUSIP No. G4617B10513GPage 12 of 15

(iii) Sole power to dispose or to direct the disposition of:	All Reporting Persons - 0
(iv) Shared power to dispose or to direct the disposition of:	Deerfield Mgmt, L.P 6,341,894 Deerfield Management Company, L.P 6,341,894 Deerfield Partners, L.P 2,317,371 Deerfield Special Situations Fund, L.P 624,965 Deerfield International Master Fund, L.P 1,264,347 Deerfield Private Design Fund II, L.P. – 995,008
	Deerfield Private Design International II, L.P. – 1,140,203 James E. Flynn - 6,341,894

\*\*See footnotes on cover pages which are incorporated by reference herein.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following .

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by theParent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit B

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

#### CUSIP No. G4617B10513GPage 13 of 15

Item 10. Certifications.

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11."

## Edgar Filing: Horizon Pharma plc - Form SC 13G/A

CUSIP No. G4617B10513GPage 14 of 15

## SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

#### DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: <u>/s/ Jonathan Isler</u>

Jonathan Isler, Attorney-In-Fact

#### DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

#### DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

## DEERFIELD SPECIAL SITUATIONS FUND, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

### DEERFIELD INTERNATIONAL MASTER FUND, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

### DEERFIELD PRIVATE DESIGN FUND II, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

### DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

CUSIP No. G4617B10513GPage 15 of 15

JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

Date: February 14, 2018

Exhibit List

Exhibit A. Joint Filing Agreement.

Exhibit B. Item 8 Statement.

Exhibit C. Power of Attorney (1).

(1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, Deerfield Mgmt IV, L.P., Deerfield Mgmt IV, Deerfield Mg

Exhibit A

Joint Filing Agreement

The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Horizon Pharma PLC shall be filed on behalf of the undersigned.

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: <u>/s/ Jonathan Isler</u>

Jonathan Isler, Attorney-In-Fact

### DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: <u>/s/ Jonathan Isler</u>

Jonathan Isler, Attorney-In-Fact

### DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

### DEERFIELD SPECIAL SITUATIONS FUND, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

### DEERFIELD INTERNATIONAL MASTER FUND, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

#### By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

## DEERFIELD PRIVATE DESIGN FUND II, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

## DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

# JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

### Exhibit B

Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a "group" with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.